135 related articles for article (PubMed ID: 10697753)
21. Pharmacokinetic evaluation in dogs of theophylline in a novel zero-order release core-in-cup tablet.
Danckwerts MP; van der Watt JG; Moodley I
Biopharm Drug Dispos; 1998 Nov; 19(8):517-22. PubMed ID: 9840213
[TBL] [Abstract][Full Text] [Related]
22. Eudragit(®) RS PO/RL PO as rate-controlling matrix-formers via roller compaction: Influence of formulation and process variables on functional attributes of granules and tablets.
Dave VS; Fahmy RM; Bensley D; Hoag SW
Drug Dev Ind Pharm; 2012 Oct; 38(10):1240-53. PubMed ID: 22257339
[TBL] [Abstract][Full Text] [Related]
23. Comparative study of the lubricant performance of Compritol 888 ATO either used by blending or by hot melt coating.
Jannin V; Bérard V; N'Diaye A; Andrès C; Pourcelot Y
Int J Pharm; 2003 Aug; 262(1-2):39-45. PubMed ID: 12927386
[TBL] [Abstract][Full Text] [Related]
24. The influence of diluent on the release of theophylline from hydrophilic matrix tablets.
Pina ME; Veiga F
Drug Dev Ind Pharm; 2000 Oct; 26(10):1125-8. PubMed ID: 11028230
[TBL] [Abstract][Full Text] [Related]
25. Swelling kinetics of spray-dried chitosan acetate assessed by magnetic resonance imaging and their relation to drug release kinetics of chitosan matrix tablets.
Huanbutta K; Sriamornsak P; Limmatvapirat S; Luangtana-anan M; Yoshihashi Y; Yonemochi E; Terada K; Nunthanid J
Eur J Pharm Biopharm; 2011 Feb; 77(2):320-6. PubMed ID: 21129484
[TBL] [Abstract][Full Text] [Related]
26. Sustained release phenylpropanolamine hydrochloride from ATO 888 matrix.
Perez MA; Ghaly ES; Marti A
P R Health Sci J; 1993 Dec; 12(4):263-7. PubMed ID: 8140204
[TBL] [Abstract][Full Text] [Related]
27. Formulation of a poorly water-soluble drug in sustained-release hollow granules with a high viscosity water-soluble polymer using a fluidized bed rotor granulator.
Asada T; Yoshihara N; Ochiai Y; Kimura SI; Iwao Y; Itai S
Int J Pharm; 2018 Apr; 541(1-2):246-252. PubMed ID: 29496456
[TBL] [Abstract][Full Text] [Related]
28. Release and diffusional modeling of metronidazole lipid matrices.
Ozyazici M; Gökçe EH; Ertan G
Eur J Pharm Biopharm; 2006 Jul; 63(3):331-9. PubMed ID: 16621486
[TBL] [Abstract][Full Text] [Related]
29. Effect of diluents on tablet integrity and controlled drug release.
Zhang YE; Schwartz JB
Drug Dev Ind Pharm; 2000 Jul; 26(7):761-5. PubMed ID: 10872095
[TBL] [Abstract][Full Text] [Related]
30. Compritol®888 ATO a lipid excipient for sustained release of highly water soluble active: formulation, scale-up and IVIVC study.
Patere SN; Desai NS; Jain AS; Kadam PP; Thatte UM; Gogtay N; Kapadia CJ; Farah N; Nagarsenker MS
Curr Drug Deliv; 2013 Oct; 10(5):548-56. PubMed ID: 23607649
[TBL] [Abstract][Full Text] [Related]
31. In vitro release--in vivo microbiological and toxicological studies on ketoconazole lipid granules.
Ozyazici M; Gokce EH; Ozer O; Ay Z; Guneri T; Ertan G; Gokce G; Metin DY; Hilmioglu S; Durmaz G; Yalcin A; Pekcetin C; Ozyurt D
Pharm Dev Technol; 2007; 12(6):581-90. PubMed ID: 18161631
[TBL] [Abstract][Full Text] [Related]
32. Preparation and characterization of Compritol 888 ATO matrix tablets for the sustained release of diclofenac sodium.
Roberts M; Pulcini L; Mostafa S; Cuppok-Rosiaux Y; Marchaud D
Pharm Dev Technol; 2015 Jun; 20(4):507-12. PubMed ID: 24354893
[TBL] [Abstract][Full Text] [Related]
33. Preparation of Sustained Release Tablet with Minimized Usage of Glyceryl Behenate Using Post-Heating Method.
Kang C; Lee JH; Kim DW; Lee BJ; Park JB
AAPS PharmSciTech; 2018 Oct; 19(7):3067-3075. PubMed ID: 30094721
[TBL] [Abstract][Full Text] [Related]
34. [Theophylline release and diffusion from a compressed ethylcellulose matrix through an artificial membrane].
Noureddine N; Douki W; Chaumeil JC; Sfar S
Ann Pharm Fr; 2004 Sep; 62(5):343-7. PubMed ID: 15314582
[TBL] [Abstract][Full Text] [Related]
35. Effect of channeling agents on the release pattern of theophylline from kollidon SR based matrix tablets.
Ibn Razzak MS; Khan F; Hossain M; Khan MZ; Azad MA; Reza MS
Pak J Pharm Sci; 2009 Jul; 22(3):303-7. PubMed ID: 19553179
[TBL] [Abstract][Full Text] [Related]
36. Influence of design parameters on sustained drug release properties of 3D-printed theophylline tablets.
Pflieger T; Venkatesh R; Dachtler M; Cooke K; Laufer S; Lunter D
Int J Pharm; 2024 Jun; 658():124207. PubMed ID: 38718971
[TBL] [Abstract][Full Text] [Related]
37. The effect of ethylcellulose molecular weight on the properties of theophylline microspheres.
Dashevsky A; Zessin G
J Microencapsul; 1997; 14(3):273-80. PubMed ID: 9147278
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the bioavailability and pharmacokinetics of two extended-release theophylline formulations in dogs.
Bach JE; Kukanich B; Papich MG; McKiernan BC
J Am Vet Med Assoc; 2004 Apr; 224(7):1113-9. PubMed ID: 15074856
[TBL] [Abstract][Full Text] [Related]
39. A multimechanistic drug release approach in a bead dosage form and in vitro predictions.
Liu Y; Schwartz JB; Schnaare RL
Pharm Dev Technol; 2003; 8(2):163-73. PubMed ID: 12760567
[TBL] [Abstract][Full Text] [Related]
40. Theophylline granule formulation prepared by the wet granulation method: comparison of in vitro dissolution profiles and estimation of in vivo plasma concentrations.
Karasulu E; Apaydin S; Ince I; Tuglular I
Eur J Drug Metab Pharmacokinet; 2006; 31(4):291-8. PubMed ID: 17315541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
